-
Loading metrics
Assessment of risk factors for virological nonsuppression following switch to dolutegravir and lamivudine, or bictegravir, emtricitabine, and tenofovir alafenamide fumarate in a real-world cohort of treatment-experienced adults living with HIV
- Shu-Yuan Lee,
- Yi-Chun Lin,
- Cheng-Pin Chen,
- Shu-Hsing Cheng,
- Shu-Ying Chang,
- Shin-Yen Ku,
- Chien-Yu Cheng
x
- Published: November 20, 2024
- https://doi.org/10.1371/journal.pone.0314003